Wegovy Pill UK is about one form of one medicine: oral semaglutide 25 mg, the tablet version of Wegovy, licensed by the MHRA on 11 June 2026.

Why the tablet has its own guide

The tablet contains the same active ingredient as the Wegovy injection, but taking it is a different routine. It is swallowed on an empty stomach with a sip of water, then you wait at least 30 minutes before eating, drinking or taking other medicines. Its dose ladder (1.5 mg, 4 mg, 9 mg, then 25 mg) also uses numbers that overlap with Rybelsus, a separate oral semaglutide for type 2 diabetes. Those details are easy to get wrong, so this site concentrates on them.

The sources behind each page

  • The UK Summary of Product Characteristics and patient information leaflet for Wegovy tablets, on the electronic Medicines Compendium.
  • The MHRA's approval announcement and the European Medicines Agency's assessment of the tablet.
  • The OASIS trials, published in The Lancet and the New England Journal of Medicine, and the US prescribing information.

The main pages list their references, and each page shows the date it was published, reviewed or last updated.

The pages

What Wegovy Pill UK does not do

It does not sell, supply, prescribe or dispense medicines, and it does not link to any provider of them. It is written by its editorial team and is independent of Novo Nordisk, with no affiliation to, endorsement from or connection with the company. Manufacturer and regulator pages are cited as sources for label information and nothing else.

Medical decisions stay with a prescriber

The Wegovy pill is a prescription-only medicine. Whether it is suitable for you is a decision for a qualified prescriber after a proper consultation, and lawful UK supply happens only through GPhC-registered pharmacies against a valid prescription. Nothing here is medical advice. Report suspected side effects through the MHRA Yellow Card scheme and speak to your GP or pharmacist.